Varicella Zoster Virus, Human, IgM, BioAssay(TM) ELISA Kit (VZV)

The United States Biological Varicella Zoster Virus, Human, IgG, BioAssay(TM) ELISA Kit is intended for the detection of IgM antibody to Varicella-Zoster virus in human serum.\n\nVaricella, more commonly known as chickenpox, and herpes zoster are known clinical manifestations of infection with varicella-zoster virus (VZV).\n\nChicken pox, the clinical syndrome usually produced as a result of the primary infection with VZV, is a highly contagious disease characterized by widely spread vesicular eruptions and fever. The disease is endemic in the U.S. and most commonly affects children from five to eight years of age, although adults and younger children, including infants, may develop chickenpox. Every two to five years, usually in the winter or spring, the number of cases increases to epidemic levels. VZV infection during early pregnancy has been implicated in congenital anomalies in rare cases. When infection occurs at term, life-threatening infections can occur in the neonate.\n\nHerpes zoster is mainly a disease of adults, with most cases appearing in samples fifty years or older. Evidence suggests that this manifestation of VZV infections results from a reactivation of virus which has remained latent in the sensory spinal ganglia after the primary infection rather than a reintroduction of the virus into the host. Fever and painful localized vesicular eruptions of the skin along the distribution of the involved nerves are the most common clinical symptoms of the condition. Zoster lesions can be mistaken for the similar lesions produced by herpes simplex virus in which recurrences are common. However, recurrences of herpes zoster are extremely rare.\n\nDetermination of the immune status of high risk individuals who are exposed to VZV, the screening for potential donors of Varicella-zoster immunoglobulin, and the diagnosis of VZV infected individuals (both pre- and postnatal) is usually accomplished by serological testing. \n\nThe various methods for the detection of VZV antibodies in a sample's serum include indirect immunofluorescence, neutralization, complement fixation and fluorescent antibody to membrane antigen (FAMA). FAMA is generally considered the most sensitive and specific of the methods, yet requires the use of cell culture which is cumbersome to perform. Clinical and correlation studies performed by Shehab and Brunell indicate that the ELISA methodology may be as sensitive and perhaps more specific than the FAMA assay. The sensitivity, specificity, and reproducibility of ELISAs are comparable to other serological tests for antibody, such as immunofluorescence, complement fixation, hemagglutination and radioimmunoassays.\n \nKit Components:\n1. Microtiter Plate, Varicella-zoster virus antigen (inactivated): 1 X 96 wells\n2. Serum Diluent: 2X30ml\n3. Calibrator (sample serum or defibrinated plasma): 1X400ul\n4. Positive Control: 1X400ul\n5. Negative Control: 1X400ul\n6. IgM (HRP) Goat x human: 2X16ml\n7. Absorbent Solution: 2X12 ml \n8. Tetramethylbenzidine (TMB): 2x15ml \n9. Wash Buffer, 20X: 1x50ml\n10. Stop Solution: 2x15ml (1N H2SO4)\n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2100-30

Size

1Kit

Applications

ELISA

Reactivities

Hum

References

1. Weller, T,H. 1904. Varicella-Herpes Zoster Virus. In: Viral and Rickettsial Infections of Man. F.L. Horstall, Jr. and I.Tamm, eds. 4th edition. pp 915-925. 2. Young, N.A. 1976. Chickenpox, measles and mumps. In: Infectious Diseases of the Fetus and Newborn Infant. J.S. Remington and J.O., Klein, eds. W.B. Saunders Company, Philadelphia. pp 521- 583 3. Ray, C.G. 1977. Chicken pox (varicella) and herpes zoster. G.W. Thorn. R.D. Adams, E. Braunwald, K.J. isse. pp 1020- 1023. 4. Gershon, A.A. 1975. Varicella in mother and infant. Problems old and new. In: Infections of the Fetus and the Newborn Infant. S. Krugman and A.A. Gershon, eds. Alan R. Liss, Inc., New York, N.Y. 5. Williamson, A.P. 1975. The Varicella-Zoster virus in the etiology of severe congenital defects. A survey of eleven reported instances. Clin. Pediatr. 14: 533-559. 6. Meyers, J.D. 1974. Congenital varicella in term infants: Risk reconsidered. J. Infect. Dis. 129: 215-217. 7. Adelstein, A.M. and J.W. Donovan. 1972. Malignant disease in children whose mothers had chickenpox, mumps, or rubella in pregnancy. Brit Med. J. 4:629-631. 8. Preblud, S.R. 1986. Varicella: Complication and Costs. Pediatrics. 78:728-35. 9. DiNicola, L.K. and J.B. Hanshaw. 1979. Congenital and neonatal varicella J. Pediatr. 94:175-76. 10. Brunell, P.A. 1976. Varicella-Zoster. In: Manual of Clinical Immunology. N.R. Rose and H. Friedman, eds. American Society of Microbiology, Washington, D.C. pp 421-422. 11. Schmidt, N.J., et al., J. Lab and Clin. Med. 66:403- 411. 12. Lyerla, H.C. and F.T. Forrester. 1978. Varicella-Zoster Virus In: Immunofluorescence Methods in Virology U.S. Department of Health, Education, and Welfare. pp 162-163. 13. Weller,T.H. and A.H. Coons. 1954. Fluorescent antibody studies with agents of Varicella and Herpes zoster propagated in vitro. Proc. Soc. Exp. Biol. Med. 87:789-794. 14. Williams, V., et al., J. Inf. Dis. 130: 669-672. 15. Shehab, Z. and P.A. Brunell. 1983. Enzyme-linked immunosorbent assay for susceptibility to Varicella. J. Infect. Dis. 148: 472-476. 16. Engvall, E., et al., Immunochemistry. 8:871-874. 17. Engvall, E.et al., Brugge Oxford. Pergamon Press. pp 553-556. 18. Engvall, E., K. Jonsson, and P. Perlman. 1971. Enzyme Linked Immunosorbent Assay. II. Quantitative Assay of Protein Antigen, Immunoglobulin-G, By Means of Enzyme-Labelled Antigen and Antibody- Coated tubes. Biochem. Biophys. Acta. 251: 427-434. 19. Van Weeman, B. K. et al., FEBS Letter. 15:232-235. 20. Bakerman, S. 1980. Enzyme Immunoassays. Lab. Mgmt. August. pp 21-29. 21. Cappel, R., De Cuyper, F. and J. De Braekeleer. 1978. Rapid detection of IgG and IgM antibodies for cytomegalovirus by the enzyme-linked immunosorbent assay (ELISA). Arch. Virol. 58: 252-258. 22. Engvall, E. et al., J. Immunol. 109: 129-135. 23. CDC/NIH Interagency Working Group. 1993. Biosafety in Microbiological and Biomedical Laboratories. 3rd Edition. U. S. Dept. of Health and serum Services, Public Health Service. pp 18-24. 24. Cradock-Watson, J.E., et al., J Hyg Camb. 82:319-336. 25. Schmidt, N.J. 1985. Varicella-Zoster Virus. In: Manual of Clinical Microbiology, 4th edition. Lennette, EH, A Balows, WJ Hausler, Jr., HJ Shadomy, eds. American Society for Microbiology, Washington, DC. 66: 720- 727. 26. Gershon, A.A. 1985. Varicella-Zoster Infections. In: Laboratory Diagnosis of Viral Infections.EH Lennette ed. Marcel Dekker, New York. 20: 329-340. 27. Arvin, A.M. et al., J Clin Micro. 12: 367-374. 28. Sundqvist, V.A. 1982. Frequency and Specificity of Varicella- Zoster Virus IgM Response. J Virol Methods. 5:219-227.29. Schmidt, N.J. et al., J Clin Micro. 23: 978-979. 30. Forghani, B, et al. 1984. Antibody Class Capture Assays for Varicella-Zoster Virus. J Clin Micro. 19:606- 609. 31. Weller, T.H. 983. Varicella and Herpes Zoster: Changing Concepts of the Natural History, Control, and Importance of Notso-Benign Virus. New Engl J Med. 309:1362. 32. Centers for Disease Control. 1983. Annual Summary Reported Morbidity and Mortality in the United States. Morbidity and Mortality Weekly Report. 32:71-72. 33. Schneweis, K.,et al., Dtsch Med Wschr. 110: 453-457. 34. National Committee for Clinical Laboratory Standards. 1990. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture Approved Standard. NCCLS Publication H18-A. 35. NCCLS. 1991. National Committee for Clinical Laboratory Standard. Internal Quality Control Testing: Principles & Definition. NCCLS Publication C24- A. 36. http://www.cap.org/html/ftpdirectory/checklistftp.html. 1998. Laboratory General - CAP (College of American Pathology) Checklist (April 1998). pp 28-32. 37. NCCLS. 1997. National Committee for Clinical Laboratory Standard. Preparation and Testing of Reagent Water in the Clinical Laboratory. NCCLS Publication C3- A3.